These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7235987)

  • 1. Mutagenicity testing of pharmaceuticals: present status. Introduction.
    Zbinden G
    Arch Toxicol; 1980 Nov; 46(1-2):1-7. PubMed ID: 7235987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Draft guidelines on mutagenicity testing of new drugs issued by the CPMP. A four test screen.
    Draper MH; Griffin JP
    Arch Toxicol; 1980 Nov; 46(1-2):9-19. PubMed ID: 7236001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How will the genotoxicity guidelines for pharmaceuticals be changed by the ICH agreement.
    Sofuni T
    J Toxicol Sci; 1996 Dec; 21(5):461-4. PubMed ID: 9035054
    [No Abstract]   [Full Text] [Related]  

  • 4. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with mutagenicity testing of new drugs: viewpoint of a regulatory agency.
    Madle S; Korte A; Bass R
    Mutat Res; 1987 Aug; 182(4):187-92. PubMed ID: 3302693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First exposure in man: toxicological considerations.
    Spindler P; Sjöberg P; Knudsen LE
    Pharmacol Toxicol; 2000; 86 Suppl 1():8-12. PubMed ID: 10905746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
    J Biol Stand; 1989 Jul; 17(3):203-12. PubMed ID: 2677013
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotoxicity tests. Considerations regarding the selection of a standard battery test.
    Shimada H
    J Toxicol Sci; 1996 Dec; 21(5):469-72. PubMed ID: 9035056
    [No Abstract]   [Full Text] [Related]  

  • 10. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
    Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
    Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of aromatic amines with different purities and different solvent vehicles in the Ames test.
    Harding AP; Popelier PL; Harvey J; Giddings A; Foster G; Kranz M
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):244-50. PubMed ID: 25542092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals.
    Müller L; Kasper P
    Mutat Res; 2000 Jan; 464(1):19-34. PubMed ID: 10633174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical carcinogens without mutagenic activity: peroxisome proliferators as a prototype.
    Reddy JK; Scarpelli DG; Subbarao V; Lalwani ND
    Toxicol Pathol; 1983; 11(2):172-80. PubMed ID: 6399165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutagenicity screening of crude drugs with Bacillus subtilis rec-assay and Salmonella/microsome reversion assay.
    Morimoto I; Watanabe F; Osawa T; Okitsu T; Kada T
    Mutat Res; 1982 Apr; 97(2):81-102. PubMed ID: 6804865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutagenicity of textile dye products.
    Schneider K; Hafner C; Jäger I
    J Appl Toxicol; 2004; 24(2):83-91. PubMed ID: 15052602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact.
    Müller L; Kikuchi Y; Probst G; Schechtman L; Shimada H; Sofuni T; Tweats D
    Mutat Res; 1999 May; 436(3):195-225. PubMed ID: 10354523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical local tolerance testing of medicinal products. CPMP Working Party on Safety of Medicinal Products.
    Pharmacol Toxicol; 1991 Mar; 68(3):233-6. PubMed ID: 2057456
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA requirements for nonclinical testing of contraceptive steroids.
    Jordan A
    Contraception; 1992 Dec; 46(6):499-509. PubMed ID: 1493710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Jun; 77(110):33748-9. PubMed ID: 22675782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.